• Appointment of new Scientific Advisory Board comprising thought leaders from academia and industry to boost pipeline progress and expansion
• New laboratories will accommodate growing team and increased activities
• Move supported by key shareholder Noshaq and SPI and confirms Imcyse’s commitment to the Walloon Region of Belgium, a leading center for talent and R&D within Europe

From start on, a major goal of INNODIA was to undertake clinical intervention studies and to pave the way for the development of novel treatments to prevent and cure Type 1 Diabetes.

INNODIA is now performing mechanistic-based clinical studies, using a Master-Protocol established within INNODIA.

• Pfizer takes equity stake in Imcyse as part of the recently announced Rheumatoid Arthritis license agreement
• Major existing shareholders participated in the round
• Proceeds to advance Imcyse’s pipeline of first-in-class targeted disease modifying immunotherapeutics